Product Description: Adeno-associated virus (AAV) vectors have been identified as an optimal vehicle for in vivo gene therapy due to their high efficiency and safety in humans. However, working with the inverted terminal repeat (ITR) regions of these vectors can be challenging.
As a global leader in genomics, Azenta Life Sciences has developed a suite of proprietary genomics protocols to simplify working with complex AAV vectors. Each of our protocols, including AAV plasmid preparation and synthesis, AAV-ITR Sanger sequencing, and whole AAV genome next generation sequencing, maintain the integrity of your AAV vectors so you can trust the quality of your packaged material for your gene therapy research.
Product Details:
RUO & GLP AAV-ITR Sanger Sequencing
Utilizes Sanger protocols to sequence-confirm difficult ITR regions, expediting screening and validation of lead candidates. Our GLP AAV-ITR sequencing is the first and only available GLP-compliant method for sequencing difficult ITR regions of AAV vectors.
Learn More >
AAV Plasmid Preparation
Ensures delivery of intact ITR regions while providing superior quality for mini-to-giga scale AAV vectors.
Learn More >
AAV Plasmid Synthesis
Enables synthesis and cloning of transgene expression cassettes into custom AAV vectors. Includes ITR correction to synthesize and clone correct ITR sequences.
Learn More >
Whole AAV Genome Next Generation Sequencing
Reimagine quality control standards for rAAV vectors by employing long-read (>10kb) NGS to verify integrity, detect heterogeneity, and reveal packaging attributes. Analyze host response utilizing RNA-Seq and a variety of other proprietary deep sequencing approaches.
Learn More >